Date:5/22/2008

s from future net sales and sublicense of belinostat may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in CuraGen's Quarterly Report on Form 10-Q for the period ended March 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, CuraGen's actual results may differ materially from any
'/>"/>

SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. CuraGen Reports First Quarter 2008 Financial Results
2. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
3. CuraGen Reports Third Quarter 2007 Financial Results
4. CuraGen to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Actifirm Sells Out in First Hour Appearance on QVC
6. Blackstone Sells Gerresheimer Stake
7. Isolagen, Inc. Sells Switzerland Facility
8. On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group
9. Medifast Franchise Systems Sells First Territory in Baltimore
10. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
11. Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses